The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
NLI Holdings Inc
NL · the NYSE · USD · 2,812 employees
NLI Holdings, Inc., through its subsidiaries, operates in the component products industry in Europe, North America, the Asia Pacific, and internationally.
PASS · Titan Ethical · score 70.0Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.36 USD at the 4 Nov 2026 close
- Fair valueUnder review: its inputs are 11 days old; there is no analyst estimate to cross-check it.
- Our regime readMarkdown, as of 4 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.27)
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-04).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.27, read 2026-11-05
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
NLI Holdings Inc holds its Markdown at $7.36. Consolidating, no directional conviction, held for 46 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 46 days |
| Price at the screen | $7.36 |
| Valuation | N/A trailing · N/A forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.20 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.11% | Below 33% | Interest-bearing debt is just 0.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 3.11% | Below 33% | Cash held in interest-bearing accounts and securities is 3.1% of assets, under the one-third limit. | Pass |
| Receivables | 26.81% | Below 49% | Money owed to the company is 26.8% of assets, under the 49% limit. | Pass |
| Revenue purity | 4.42% | Below 5% | Only 4.4% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
NLI clears all five screens. Its business is in a permissible area, its debt is near-nil, and interest is about 4% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NL's ethical verdict changes
Today NL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Its inputs are 11 days old; there is no analyst estimate to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
Price History & ProjectionsWhere our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| EPS, trailing | -0.52 |
| Revenue growth | +8.0%slow but positive growth |
| Profit margin | -15.8%currently unprofitable |
| Return on equity | -5.7%not currently earning a positive return on equity |
| Dividend yield | 661.00% |
| Debt to equity | 0.37minimal debt: a conservative balance sheet |
| Current ratio | 9.02comfortably covers its short-term bills |
| Beta | 0.20barely tracks the market's swings |
| Short interest, float | 0.02% |
| 52-week range | 5.04 - 8.60 |
| Moat | NONE |
| Employees | 2,812 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNL trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%. Since the last review it its composite score eased.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 28%.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- NL Upgraded to Outperform on CompX Strength, Kronos Recovery Yahoo Finance · 23 Sep 2026
- The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio Zacks · 11 Sep 2026
- The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio Yahoo Finance · 11 Sep 2026
- Top Research Reports for Goldman Sachs, RTX & Abbott Zacks · 10 Sep 2026
- Top Research Reports for Goldman Sachs, RTX & Abbott Yahoo Finance · 10 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-10 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-10 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-10 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-05-27 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-05-21 | Ro Khanna | Democrat | buy | 100K–250K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $5.71 | +5.6% | $0.10 | $1,073 | +7.3% |
| 2 months | $5.71 | +5.6% | $0.10 | $1,073 | +7.3% |
| 3 months | $5.86 | +2.9% | $0.10 | $1,046 | +4.6% |
| 6 months | $5.60 | +7.7% | $0.20 | $1,112 | +11.2% |
| 1 year | $6.61 | -8.8% | $0.59 | $1,001 | +0.1% |
| 2 years | $5.59 | +7.9% | $1.44 | $1,336 | +33.6% |
| 3 years | $4.59 | +31.2% | $1.66 | $1,674 | +67.4% |
| 5 years | $5.30 | +13.7% | $2.55 | $1,618 | +61.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NL does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.